Last updated: April 25, 2026
Who supplies fluocinolone acetonide drug substance (API)?
The market for fluocinolone acetonide is concentrated around a small group of global API manufacturers with filings across the major regulatory zones (US, EU, UK, and ROW). Public supplier visibility varies by jurisdiction and by whether the supplier appears as an API source on product labels, registration dossiers, or regulatory lists.
API supply chain pattern (what to expect in practice)
For fluocinolone acetonide, downstream manufacturers typically source API through:
- Synthetic API producers (CMC manufacturers that file DMFs or equivalent registrations in target jurisdictions).
- Specialty distributors / traders (often the direct commercial counterparty for smaller formulators).
- Regional finished-goods manufacturers (who may integrate API supply or buy it through approved sourcing frameworks).
Practical supplier targets (categories)
Use these target buckets when mapping procurement:
- DMF-backed API producers for “Fluocinolone Acetonide” or “Fluocinolone acetate” (INN variations).
- Steroid API suppliers with a glucocorticoid portfolio (derivatives like acetonides).
- Contract API manufacturers that support GMP commercial supply and scale-up.
Which companies supply fluocinolone acetonide finished dosage forms?
Fluocinolone acetonide is marketed in multiple topical forms (cream/ointment/scalp oil/solutions) and is also used in ophthalmic contexts for certain indications. Finished-goods supply is spread across branded and generic manufacturers.
Finished product supplier map (how to build it correctly)
A correct finished-goods supplier map is product-specific and strength-specific:
- Topicals (cream/ointment/solution/oil): suppliers show up as MAHs/labelers on local product registers and on FDA/EMA product information where applicable.
- Ophthalmics: supplier mapping is driven by approved strengths and packaging listings, which differ by country.
How to identify fluocinolone acetonide suppliers with proof (procurement-grade method)
The fastest procurement-grade method is to pull:
- Regulatory product labels for each target market (US FDA Orange Book for generics; EU national registers for MAHs).
- API source disclosures where available (DMF/CEP references, manufacturer lists in registration summaries, or publicly indexed DMF/CEP holder info).
- GMP supplier verification: GMP certificates for the API site (and drug product site where relevant).
Data fields that must be captured for each supplier
For every supplier you shortlist, record:
- Regulatory identity: site name and address
- Scope: API vs finished dosage form
- Strength/grade: anhydrous vs hydrate status (if applicable) and particle spec if disclosed
- Compliance: GMP certificate issuing authority and inspection date
- Documentation: DMF/CEP/other registration identifiers (where present)
What supplier specs matter for fluocinolone acetonide API procurement?
Procurement for corticosteroid APIs typically hinges on:
- Assay/potency
- Impurities profile (including known steroid-related impurities)
- Solubility-related attributes relevant to formulation
- Particle size / solid-state form (especially for topical suspension-type products)
- Residual solvents (if produced with solvent-based steps)
- Stability / shelf-life data under ICH conditions
Key commercial sourcing decision points
Single-source vs dual-source
Fluocinolone acetonide tends to be a manageable category for dual sourcing due to the number of downstream formulation players, but actual dual sourcing depends on:
- Your target dosage form
- Your region’s approval status
- Your required documentation level (DMF access, supplier change control, impurity set, analytical method transfer readiness)
Direct API buy vs contract manufacturing
Common routing patterns:
- Buy API directly when you control formulation tech transfer and regulatory filing ownership.
- Use CDMO when you need fast readiness for clinical/commercial packaging and local regulatory submissions.
Key Takeaways
- Supplier identification for fluocinolone acetonide must be built from market-specific finished product labelers (MAHs/manufacturers) and API registration-backed sites, not generic “drug supplier” lists.
- Procurement-grade mapping requires capturing site-level GMP evidence, regulatory identifiers (DMF/CEP where disclosed), and spec/impurity expectations for the corticosteroid API.
- Finished-goods suppliers are product-form and strength dependent, so supplier lists must be assembled per dosage form and market.
FAQs
-
Is “fluocinolone acetate” the same as fluocinolone acetonide for sourcing?
They are used interchangeably in many procurement contexts; confirm identity via INN/USP/EP naming and supplier COA.
-
What is the main procurement risk for fluocinolone acetonide API?
Risk concentrates in impurity profile consistency, documentation access (DMF/registration links), and change control for synthesis routes.
-
Who do I contact first for API sourcing?
DMF/CEP holders or API GMP certificate holders for drug substance supply; distributors typically require you to back-map to the actual manufacturing site.
-
Do different fluocinolone acetonide products require different API specs?
Often yes. Topical formulation needs can drive particle/solubility and impurity controls beyond baseline pharmacopoeial specs.
-
Can the same supplier provide both API and the finished dosage form?
Yes, but it is not automatic. Many suppliers specialize in either API or finished-goods; due diligence should be site-based, not brand-based.
References
[1] FDA. Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Food and Drug Administration. https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm
[2] EMA. European Medicines Agency: Product information and EPAR search. European Medicines Agency. https://www.ema.europa.eu/en/medicines
[3] USP. Fluocinolone Acetonide monograph and related standards. United States Pharmacopeia. https://www.uspnf.com
